AngioDynamics (NASDAQ:ANGO – Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of -0.380–0.340 for the period, compared to the consensus earnings per share estimate of -0.400. The company issued revenue guidance of $282.0 million-$288.0 million, compared to the consensus revenue estimate of $283.9 million.
Analysts Set New Price Targets
Several research analysts have weighed in on the stock. Canaccord Genuity Group lowered their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, October 4th. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a research note on Tuesday, December 10th.
Check Out Our Latest Stock Analysis on AngioDynamics
AngioDynamics Stock Performance
AngioDynamics (NASDAQ:ANGO – Get Free Report) last issued its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. Sell-side analysts anticipate that AngioDynamics will post -0.41 EPS for the current year.
About AngioDynamics
AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.
Read More
- Five stocks we like better than AngioDynamics
- Compound Interest and Why It Matters When Investing
- Top 2 Auto Maintenance Stocks Gearing Up for 2025
- What is a SEC Filing?
- 100% Upside? Amprius Technologies Is Charged for Growth in 2025
- What is Forex and How Does it Work?
- The 5 Stocks Congress Bought Most in 2024: Top Picks for 2025
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.